Should I Buy PCRX? PCRX 2026 Analysis

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

23.150

1 Day change

-2.07%

52 Week Range

27.640

Analysis Updated At

2026/04/24

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Given the mixed financial performance, lack of strong proprietary trading signals, and limited near-term positive momentum, Pacira Biosciences Inc (PCRX) does not present a compelling buy opportunity for a beginner, long-term investor at this time. The stock's technical indicators are bullish, but the financials and analyst sentiment suggest caution. Holding off on investment until clearer growth signals emerge would be prudent.

Technical Analysis

The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 77.262, and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 25.212), indicating limited immediate upside potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are significantly increasing their positions in the stock, suggesting institutional confidence. Analysts highlight the potential for reduced opioid usage and cost savings with Exparel in specific medical procedures.

Neutral/Negative Catalysts

Insiders are selling shares, with a 254.66% increase in selling activity over the last month. Barclays lowered the price target to $25, citing limited near-term momentum due to pipeline updates being back-half weighted. Financial performance shows significant declines in net income (-89.79% YoY) and EPS (-88.57% YoY).

Financial Performance

In Q4 2025, revenue increased by 5.14% YoY to $196.87M, but net income dropped sharply by 89.79% YoY to $1.64M. EPS also fell by 88.57% YoY to $0.04. Gross margin improved slightly to 72.26%, up 1.70% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating with a $38 price target, citing the value proposition of Exparel in reducing opioid usage and healthcare costs. However, Barclays downgraded the price target to $25, maintaining an Equal Weight rating due to limited near-term momentum.

6 Analyst Rating

Wall Street analysts forecast PCRX stock price to rise

4 Buy

1 Hold

1 Sell

Moderate Buy

Current: 23.150

Low

Averages

30.33

High

Current: 23.150

Low

Averages

30.33

High

Needham

Buy

maintain

$30 -> $32

AI Analysis

2026-05-01

Reason

Needham

Price Target

$30 -> $32

AI Analysis

2026-05-01

maintain

Buy

Reason

Needham raised the firm's price target on Pacira to $32 from $30 and keeps a Buy rating on the shares after its Q1 earnings beat. The company's Q1 volume was up 7%, in line with growth seen in 2025, as it continues to expect similar volume growth and improved pricing dynamics once final GPO contract lapses in the middle of this year, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$38

2026-04-13

Reason

H.C. Wainwright

Price Target

$38

2026-04-13

maintain

Buy

Reason

H.C. Wainwright says the real-world data on Exparel indicate it can lead to lower or comparable total healthcare costs and reduced opioid usage. Pacira presented real-world data supporting the payer value proposition of liposomal bupivacaine, the analyst tells investors in a research note. The firm believes the strength of the evidence appears to depend on the specific procedure, with a more compelling economic signal observed in total hip arthroplasty compared to total knee arthroplasty. While the data in total hip arthroplasty pointed to meaningful cost savings, the total knee arthroplasty data points to cost parity, though that doesn't fully capture clinical benefits or patient satisfaction benefits that use of Exparel may provide, contends H.C. Wainwright. The firm believes the data highlights a reduction in opioid usage at six months post-surgery among patients with low back pain who underwent total hip arthroplasty. It keeps a Buy rating on Pacira with a $38 price target. The stock in midday trading is up 1% to $24.11.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCRX

Unlock Now

PCRX Should I Buy

PCRX Should I Buy

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch